Blood Sampling of Healthy Volunteers for Immunological Research

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03819829

Enrollment

Registered

2019-01-29

Start date

2019-02-05

Completion date

2027-12-02

Last updated

2023-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

This protocol will be used to collect crucial components of the immune system from healthy volunteers for the characterization of immune cells in fresh blood. A pipeline has been set up for comprehensive immune phenotyping of both lymphoid and myeloid cells within 24 hours after blood withdrawal.

Detailed description

In order to properly compare the immunobiology of healthy volunteers to (advanced) cancer patients, the investigators use age-matched controls with no history of cancer and no potentially interfering medication. Healthy volunteers will be asked to donate 5 tubes of blood

Interventions

OTHERBlood sample

Blood sample

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

36 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age above 35 years * Written informed consent * No history of cancer * No use of systemic immunosuppressive medication (eg. corticosteroids). Local use of corticosteroids (eg. topical or inhalation) is allowed.

Exclusion criteria

* Fever 14 days before blood withdrawal * Donated blood for the same program within the last 2 years * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
The number of immune cells, both lymphoid and myeloid, present in the blood of healthy individuals, assessed by flow cytometry, as well as cytokine expression and transcriptome profiles of these cells	assessed up to 12 months	the number of lymphoid and myeloid immune cells present in the blood of healthy individuals using flow cytometry, assessing the cytokine expression of these cells in healthy individuals using ELISA cytokine assays, and assessing gene expression of these cells using single cell transcriptomics analyses using droplet-based single cell RNA sequencing.

Secondary

Measure	Time frame	Description
Immunophenotyping of both myeloid and lymphoid cells in healthy individuals	assessed up to 12 months	Immunophenotyping of both myeloid and lymphoid cells in healthy controls to gain insights in immunological defects and immune evasion in cancer patients

Countries

Netherlands

Contacts

Primary ContactM Kok, MD

m.kok@nki.nl3120512

Backup ContactL Voorwerk, MD

l.voorwerk@nki.nl3120512

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026